Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Visceral Leishmaniasis Market Size Changed, over the years?
In the last few years, the market size of visceral leishmaniasis has seen a robust growth. The market is set to increase from $1.00 billion in 2024 to $1.06 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. The factors contributing to the growth during the historic period include an increase in disease burden, surge in government funding, launch of amphotericin B, advancement of miltefosine, expansion of awareness campaigns, better accessibility to healthcare in endemic areas, and the foundation of public-private alliances.
How Much Will the Visceral Leishmaniasis Market Be Worth in 2029?
In the upcoming years, the market size for visceral leishmaniasis is set to witness substantial growth, with a projected worth of $1.33 billion in 2029, driven by a compound annual growth rate (CAGR) of 5.8%. Several factors can account for this growth in the forecast period, such as increased investment in the development of vaccines, heightened worldwide disease monitoring programs, growth in public-private partnerships, better funding for overlooked tropical diseases, and the introduction of gene-based therapies. Key trends predicted for this period include CRISPR-based gene alterations, AI-aided drug discovery, nanotechnology-improved drug delivery, next-gen sequencing for parasite examination, wearable biosensors for prompt detection, the application of blockchain for medical supply chain control, smartphone-driven diagnostic mechanisms, and 3D bioprinting geared towards personalized treatment research.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp
Which is the Largest Company in the Visceral Leishmaniasis Market?
Major companies operating in the visceral leishmaniasis market are Pfizer Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd, Xellia Pharmaceuticals, Knight Therapeutics Inc, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, TLC.
What Are the Main Market Drivers in the Visceral Leishmaniasis Industry?
The escalation in malnutrition levels is predicted to spur the expansion of the visceral leishmaniasis market. Malnutrition, a health issue resulting from insufficient or unbalanced intake of key nutrients required for bodily functions, has been on the rise due to food insecurity. This insecurity impedes access to nutritious food, prompting undernourishment and micro-nutrient insufficiencies, subsequently compromising the immune system. An impaired immune system heralds an increased susceptibility to infections, including visceral leishmaniasis. The body’s defense mechanisms are weakened by nutrient deficiencies, thereby augmenting the risk of intensified diseases and complications. For example, the Food and Agriculture Organization, an Italy-based specialized agency of the United Nations, reported in July 2024 that the count of undernourished people had elevated to 723.8 million in 2022, which was higher than 708.7 million in 2021. In consequence, malnutrition’s rise is fuelling the growth of the visceral leishmaniasis market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23573&type=smp
How Is the Visceral Leishmaniasis Market Segments Structured?
The visceral leishmaniasis market covered in this report is segmented –
1) By Treatment: Antiparasitic, Antifungal, Other Treatments
2) By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods
3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Antiparasitic: Pentavalent Antimonials, Miltefosine, Paromomycin, Sitamaquine, Combination Therapy
2) By Antifungal: Amphotericin B, Liposomal Amphotericin B (AmBisome), Azoles, Echinocandins, Polyenes
3) By Other Treatments: Immunotherapy, Monoclonal Antibodies, Vaccine-Based Approaches, Photodynamic Therapy, Gene Therapy
What Strategic Trends Are Transforming the Visceral Leishmaniasis Market?
Leading firms in the visceral leishmaniasis market are placing emphasis on the progression of treatment alternatives, such as antiparasitic drugs, to heighten effectiveness and boost patient access, particularly in areas heavily affected by the disease. Antiparasitic drugs, which are used to treat parasitic infections, operate by interfering with the parasite’s biological processes, limiting its growth, reproduction, or survival. For example, in February 2024, Zydus Lifesciences Limited, a pharmaceutical company based in India, was granted prequalification approval by the World Health Organization (WHO) for the active pharmaceutical ingredient (API) and formulation of miltefosine, used to treat leishmaniasis, also known as kala-azar. Miltefosine, an oral antiparasitic drug, functions by damaging the parasite’s cell membrane and disrupting its metabolism, causing cell death. Additionally, it inhibits parasite growth and ensures survival, making it a potent oral therapy for visceral leishmaniasis or kala azar.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report
Which Global Regions Offer the Highest Growth in the Visceral Leishmaniasis Market?
North America was the largest region in the visceral leishmaniasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23573
This Report Delivers Insight On:
1. How big is the visceral leishmaniasis market, and how is it changing globally?
2. Who are the major companies in the visceral leishmaniasis market, and how are they performing?
3. What are the key opportunities and risks in the visceral leishmaniasis market right now?
4. Which products or customer segments are growing the most in the visceral leishmaniasis market?
5. What factors are helping or slowing down the growth of the visceral leishmaniasis market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
